|
مقاله
|
Abstract
|
|
|
|
Title:
|
Anti-vascular Endothelial Growth Factor Effect of Topical Timolol for Non-center-involving Diabetic Macular Edema
|
|
Author(s):
|
Khalil Ghasemi Falavarjani MD, Yasaman Hadi MD, Samira Jafari MD, Mohammad Mehdi Parvaresh MD, Mehdi Modarres MD, Masoud Naseripour MD, Ahad Sedaghat MD, Sayyed Amirpooya Alemzadeh MD, Pasha Anvari MD
|
|
Presentation Type:
|
Poster
|
|
Subject:
|
Posterior Segment
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Pasha Anvari
|
|
Affiliation :(optional)
|
Eye Research Center and Eye Department, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
|
|
E mail:
|
panvari@student.tums.ac.ir
|
|
Phone:
|
88010558
|
|
Mobile:
|
09122490767
|
|
|
|
|
Purpose:
|
To evaluate the anti-vascular endothelial growth factor effect of topical timolol in patients with non-center involving diabetic macular edema
|
|
Methods:
|
In this prospective, interventional case series subjects with non-center-involving diabetic macular edema were treated with topical timolol twice daily for at least three months. Macular thickness at thickest point was measured at baseline, one month and three months
|
|
Results:
|
Twenty-one eyes of 16 subjects with mean age of 57.09 ±5.98 years (range: 48 to 71) were included. Macular thickness at thickest point was 408.80 ±37.13 (range: 364 to 492) µm, 390.47 ±37.91 µm (range: 307 to 465) and 383.00 ± 30.76 µm (range: 337 to 454)at baseline, one month and three months, respectively. Repeated measure ANOVA revealed that the reduction in macular thickness was significant at one and three months compared with baseline (P=0.005 and P=0.001, respectively).
|
|
Conclusion:
|
Topical timolol is effective for reducing non-center-involving diabetic macular edema. This effect may be mediated by its anti-vascular endothelial growth factor activity.
|
|
Attachment:
|
210timolol.pptx
|
|
|